Last reviewed · How we verify

NCT05305248

Sedation With Remimazolam During Spinal Anesthesia

Completed NA Last updated 12 May 2023
What this trial tests

NA trial testing Remimazolam in Sedation in 62 participants. Completed in 15 September 2022.

Timeline
19 April 2022
Primary endpoint
15 September 2022
15 September 2022

Quick facts

Lead sponsorGangnam Severance Hospital
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposeprevention
Enrollment62
Start date19 April 2022
Primary completion15 September 2022
Estimated completion15 September 2022
Sites1 location across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

Gangnam Severance Hospital

Who can join

19 and older, any sex, with Sedation or Spinal Anesthesia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Remimazolam is a benzodiazepine-binding site antagonist of the GABA receptor, metabolized by esterases, and exhibits a stable context-sensitive half-life of 6-7 minutes. Remimazolam has a high clearance rate and a small volume of distribution in the pharmacokinetic model. The US FDA has approved sedation for surgery. Although there have been studies on the use of remimazolam as a sedative for procedures such as endoscopy, there have been no reports of the use of remimazolam in spinal anesthesia. The purpose of this study is to compare and analyze the hemodynamics and recovery profile of patients undergoing surgery under spinal anesthesia by maintaining sedation with dexmedetomidine or remimazolam.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Remimazolam

Trials testing the same drug.

Other recruiting trials for Sedation

Currently open trials in the same condition.

Other Gangnam Severance Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05305248.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing